MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7150/thno.75847

Медицинская библиотека · Theranostics · 2022

Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis.

Kraus Sabrina, Klassen Philipp, Kircher Malte, Dierks Alexander, Habringer Stefan, Gäble Alexander, Kortüm Klaus Martin, Weinhold Niels, Ademaj-Kospiri Valëza, Werner Rudolf A, Schirbel Andreas, Buck Andreas K, Herhaus Peter, Wester Hans-Jürgen, Rosenwald Andreas, Weber Wolfgang A, Einsele Hermann, Keller Ulrich, Rasche Leo, Lapa Constantin

СтатьяПеревод пока не подготовлен

Аннотация

Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic 68Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact.

Methods

Eighty-seven MM patients underwent molecular imaging with 68Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUVpeak) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters.

Results

68Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by 68Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUVpeakSpleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; P < 0.001). Moreover, reduced splenic 68Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUVpeakSpleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUVpeakSpleen >5.79 (P < 0.001). Multivariate Cox analysis confirmed SUVpeakSpleen as an independent predictor of survival (HR 0.75; P = 0.009).

Conclusion

These data suggest that splenic 68Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted.

Для цитирования: Kraus Sabrina, Klassen Philipp, Kircher Malte, Dierks Alexander, Habringer Stefan, Gäble Alexander, Kortüm Klaus Martin, Weinhold Niels, Ademaj-Kospiri Valëza, Werner Rudolf A, Schirbel Andreas, Buck Andreas K, Herhaus Peter, Wester Hans-Jürgen, Rosenwald Andreas, Weber Wolfgang A, Einsele Hermann, Keller Ulrich, Rasche Leo, Lapa Constantin. Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis.. Theranostics. 2022. DOI: 10.7150/thno.75847.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.